Uptake and Tolerance of Chemotherapy in Elderly Patients with Small Cell Lung Cancer and Impact on Survival
Table 2
Association of demographic/clinical characteristics and receipt/tolerance of chemotherapy of patients diagnosed with SCLC aging 75 years and older who had an oncologist-consult.
Consult with an oncologist
Began chemotherapy
Dose reduction
Incomplete chemotherapy cycles
(%)1
(%)2
(%)3
(%)3
Total
171 (100)
117 (68)
40 (34)
56 (48)
Sex
= 0.53
= 0.34
= 0.20
Male
97 (57)
66 (68)
25 (38)
35 (53)
Female
74 (43)
51 (69)
15 (29)
21 (41)
Age at diagnosis
= 0.15
= 0.09
= 0.76
75–79
111 (65)
82 (74)
24 (29)
40 (49)
≥80
60 (35)
35 (58)
16 (46)
16 (46)
Year of diagnosis
= 0.19
= 0.90
= 0.08
2004
32 (19)
17 (53)
6 (35)
3 (18)
2005
35 (20)
28 (80)
8 (29)
17 (61)
2006
36 (21)
24 (67)
9 (38)
13 (54)
2007
36 (21)
23 (64)
7 (30)
11 (48)
2008
32 (19)
25 (78)
10 (40)
12 (48)
Stage
= 0.02
= 0.78
= 0.13
Extensive
131 (77)
83 (63)
28 (33)
43 (52)
Limited
38 (22)
33 (87)
12 (36)
12 (36)
Unknown
2 (1)
1 (50)
0 (0)
1 (100)
ECOG
= 0.23
= 0.18
= 0.0074
0, 1 and 2
70 (40)
59 (84)
24 (41)
22 (37)
3 and 4
71 (42)
40 (56)
11 (28)
26 (65)
Missing
30 (18)
18 (60)
5 (28)
8 (44)
Number of co-morbidities
= 0.844
= 0.514
= 0.894
0
16 (9)
13 (81)
5 (38)
7 (54)
1
64 (38)
41 (64)
16 (39)
18 (44)
2
50 (29)
30 (60)
8 (27)
16 (53)
≥3
41 (24)
33 (80)
11 (33)
15 (45)
Column percentage.
2Row percentage: denominator is the number who had a consult in corresponding row.
3Row percentage: denominator is the number who began chemotherapy in corresponding row.
4 values based on Cochran-Armitage test for trend.
